Tag Archives: Phil Nadeau

Dynavax Received its Third Buy in a Row

After Cantor Fitzgerald and William Blair assigned a Buy rating to Dynavax in the last month, the company received another Buy, this time from Cowen & Co.. Analyst Phil Nadeau maintained a Buy rating on Dynavax (NASDAQ: DVAX) yesterday and

Cowen & Co. Maintains Their Buy Rating on Spark Therapeutics

Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Spark Therapeutics (NASDAQ: ONCE) today and set a price target of $85. The company’s shares opened today at $69.77. According to TipRanks.com, Nadeau is a 5-star analyst with an

Cowen & Co. Keeps a Buy Rating on Neurocrine

Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Neurocrine (NASDAQ: NBIX) today and set a price target of $100. The company’s shares opened today at $83.59. According to TipRanks.com, Nadeau is a 5-star analyst with an average

Acorda Therapeutics Gets a Buy Rating from Cowen & Co.

In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on Acorda Therapeutics (NASDAQ: ACOR), with a price target of $30. The company’s shares opened today at $22.50. According to TipRanks.com, Nadeau is a 5-star

Cowen & Co. Keeps a Buy Rating on Vertex Pharmaceuticals

Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Vertex Pharmaceuticals (NASDAQ: VRTX) yesterday and set a price target of $200. The company’s shares opened today at $156.05. According to TipRanks.com, Nadeau is a 5-star analyst with an

Cowen & Co. Sticks to Its Hold Rating for Regeneron

Cowen & Co. analyst Phil Nadeau maintained a Hold rating on Regeneron (NASDAQ: REGN) today and set a price target of $400. The company’s shares opened today at $317, close to its 52-week low of $299.56. According to TipRanks.com, Nadeau